Results 171 to 180 of about 29,954 (264)
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi +11 more
wiley +1 more source
[Diagnosis and management of diabetes and co-existing osteoporosis (Update 2026)]. [PDF]
Muschitz C +4 more
europepmc +1 more source
Clinical Care and Rehabilitation in Neuromuscular Disorders-Why It Highly Matters. [PDF]
Gdynia HJ.
europepmc +1 more source
Astrocyte heterogeneity in brain metastases
Astrocytes emerge as pivotal regulators of metastatic colonization, survival, immune remodeling, and therapy response associated with an increasing heterogeneity that requires spatially and longitudinally resolved approaches to uncover regulatory programs and guide context‐specific therapies.
Carolina Hernández‐Oliver +2 more
wiley +1 more source
From Dish to Trial: Building Translational Models of ALS. [PDF]
Salamotas I +6 more
europepmc +1 more source
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB): A Translational Pharmacodynamic Biomarker for PIKfyve Inhibition With VRG50635. [PDF]
Gontier G +18 more
europepmc +1 more source

